Valiltramiprosate-d6

Valiltramiprosate-d6 (ALZ-801-d6) is deuterium labeled Valiltramiprosate. ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease[2].

Product Specifications

Product Name Alternative

ALZ-801-d6

UNSPSC

12352211

Target

Amyloid-β; Isotope-Labeled Compounds

Related Pathways

Neuronal Signaling; Others

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=S(C([2H])([2H])C([2H])([2H])C([2H])([2H])NC([C@@H](N)C(C)C)=O)(O)=O

Molecular Formula

C8H12D6N2O4S

Molecular Weight

244.34

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32 (9) : 849–861.|[3]Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57 (3) :315-333.